Clinical Trials
5
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (60.0%)Phase 1
2 (40.0%)Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Phase 1
- Conditions
- Lymphoma, Non-HodgkinLymphoma, T-Cell
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 71
- Registration Number
- NCT05557903
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Najing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)
Phase 3
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2018-01-03
- Target Recruit Count
- 216
- Registration Number
- NCT02786407
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
Phase 1
- Conditions
- Meningococcal Meningitis
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2015-06-25
- Target Recruit Count
- 200
- Registration Number
- NCT02481232
- Locations
- 🇨🇳
Hubei CDC, Wuhan, Hubei, China
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
Phase 3
- Conditions
- Chronic Migraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2018-01-03
- Target Recruit Count
- 288
- Registration Number
- NCT02291380
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
Phase 3
Completed
- Conditions
- Cerebrovascular Accident
- Interventions
- Drug: placebo
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2016-09-26
- Target Recruit Count
- 180
- Registration Number
- NCT02280083
News
No news found